KROS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Keros Therapeutics Inc (KROS) is not a strong buy at this time for a beginner investor with a long-term strategy. While the stock is oversold based on RSI and has potential for a short-term rebound, the company's financials show significant losses, and there are no strong positive trading signals or catalysts to justify immediate investment. Holding off for further developments or improved financial performance is recommended.
The stock is in an oversold condition with an RSI of 13.742, indicating potential for a short-term rebound. However, the MACD is negatively expanding, suggesting bearish momentum. The stock is trading below the pivot level of 15.929, with key support at 14.949 and resistance at 16.908. Moving averages are converging, showing no clear trend.
The appointment of Charles Newton to the Board of Directors could bring strategic value to the company, particularly in advancing its lead candidates rinvatercept and elritercept. The company is focused on innovative therapeutics targeting the TGF-β protein family, which could have long-term growth potential.
Additionally, Carl Gordon, a key board member, is stepping down, which may create uncertainty. The MACD indicates bearish momentum, and there are no strong trading trends from hedge funds or insiders.
In Q3 2025, revenue increased significantly by 3575.77% YoY to $14.26M, but net income dropped to -$7.28M, reflecting a significant loss. EPS also declined to -0.18, down 87.23% YoY, highlighting ongoing financial struggles despite revenue growth.
No recent analyst rating or price target updates are available for KROS.
